Business Description
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Business History
Price History (1 Year)
Key Metrics
EPS (Diluted): N/A
Total Equity: N/A
Shares: N/A
Total Debt: $0.00
Cash: $0.00
EBITDA: N/A
Total Debt: $0.00
Cash: $0.00
Revenue: N/A
Shares: N/A
Revenue: N/A
Revenue: N/A
Revenue: N/A
Total Equity: N/A
Tax Rate: N/A
Equity: N/A
Total Debt: $0.00
Cash: $0.00
Current Liabilities: N/A
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: N/A
Shares: N/A
Shares: N/A
CapEx: $0.00
Shares: N/A
Stock Price: $6.22
Net Income: N/A
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement
Requires paid FMP plan for this ticker
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 3:31am (5h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$225.8M $223.7M – $229.9M
|
$243.4M $242.5M – $244.3M
|
$264.5M $261.4M – $267.9M
|
$285.0M $281.7M – $288.7M
|
| EBITDA |
$46.4M $45.9M – $47.2M
|
$50.0M $49.8M – $50.1M
|
$54.3M $53.7M – $55.0M
|
$58.5M $57.8M – $59.2M
|
| Net Income |
-$17.1M -$28.2M – -$6.1M
|
-$7.6M -$7.7M – -$7.5M
|
-$20.3M -$20.6M – -$20.0M
|
-$18.9M -$19.2M – -$18.6M
|
| EPS | — | — | — | — |
Insider Trading (Recent)
Last updated: Jun 27, 2026 3:31am (5h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Brust Bernd | F-InKind | 351,001.00 | $5.02 | $1.8M |
| 2026-06-09 | ORESHACK KURT | S-Sale | 25,000.00 | $5.06 | $126,500 |
| 2026-06-10 | ORESHACK KURT | S-Sale | 25,000.00 | $5.10 | $127,500 |
| 2026-06-09 | LUCIER GREGORY T | G-Gift | 46,293.00 | $0.00 | $0 |
| 2026-06-09 | LUCIER GREGORY T | G-Gift | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | LUCIER GREGORY T | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | MARKER LUKE JOSEPH | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | GRAY SUSANNAH | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | MIHAS CONSTANTINE S | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | ECKERT R ANDREW | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | LUCIER GREGORY T | A-Award | 46,293.00 | $4.38 | $202,763 |
| 2026-05-26 | CUNNINGHAM SEAN LAURENCE | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-26 | DeFord John A | A-Award | 46,293.00 | $0.00 | $0 |
| 2026-05-15 | Dolan Christine | A-Award | 5,006.00 | $1.79 | $8,961 |
| 2026-05-15 | ORESHACK KURT | A-Award | 776.00 | $2.84 | $2,204 |
| 2026-03-16 | Dolan Christine | F-InKind | 28,661.00 | $3.08 | $88,276 |
| 2026-03-16 | ORESHACK KURT | F-InKind | 39,976.00 | $3.08 | $123,126 |
| 2026-01-15 | Dolan Christine | F-InKind | 28,934.00 | $3.69 | $106,766 |
| 2026-01-15 | ORESHACK KURT | F-InKind | 31,902.00 | $3.69 | $117,718 |
| 2025-12-08 | LUCIER GREGORY T | P-Purchase | 48,528.00 | $3.67 | $178,098 |
Narrative Economics
market-narrative step).